Home
HelpTest Code GID2 Gastrointestinal Dysmotility, Autoimmune/Paraneoplastic Evaluation, Serum
Ordering Guidance
Multiple neurological phenotype-specific autoimmune/paraneoplastic evaluations are available. For more information as well as phenotype-specific testing options, refer to Autoimmune Neurology Test Ordering Guide.
When more than one evaluation is ordered on the same order number the duplicate will be canceled.
For a list of antibodies performed with each evaluation, see Autoimmune Neurology Antibody Matrix.
This test should not be requested in patients who have recently received radioisotopes, therapeutically or diagnostically, because of potential assay interference. The specific waiting period before specimen collection will depend on the isotope administered, the dose given, and the clearance rate in the individual patient. Specimens will be screened for radioactivity prior to analysis. Radioactive specimens received in the laboratory will be held 1 week and assayed if sufficiently decayed or canceled if radioactivity remains.
Necessary Information
Provide the following information:
-Relevant clinical information
-Ordering provider name, phone number, mailing address, and e-mail address
Specimen Required
Patient Preparation: For optimal antibody detection, specimen collection is recommended prior to initiation of immunosuppressant medication or intravenous immunoglobulin (IVIg) treatment.
Supplies: Sarstedt Aliquot Tube, 5 mL (T914)
Collection Container/Tube:
Preferred: Red top
Acceptable: Serum gel
Submission Container/Tube: Plastic vial
Specimen Volume: 4 mL
Collection Instructions: Centrifuge and aliquot serum into a plastic vial.
Useful For
Investigating unexplained weight loss, early satiety, anorexia, nausea, vomiting, constipation, or diarrhea in a patient with a past or family history of cancer or autoimmunity
Directing a focused search for cancer
Investigating gastrointestinal symptoms that appear in the course or wake of cancer therapy, not explainable by recurrent cancer, metastasis, or therapy; detection of autoantibodies on this profile helps differentiate autoimmune gastrointestinal dysmotility from the effects of chemotherapy
Detecting early evidence of cancer recurrence in previously seropositive patients who have a rising titer of 1 or more autoantibodies
Profile Information
| Test ID | Reporting Name | Available Separately | Always Performed |
|---|---|---|---|
| AGIDI | GI Dysmotility, Interpretation, S | No | Yes |
| GANG | AChR Ganglionic Neuronal Ab, S | No | Yes |
| ANN1S | Anti-Neuronal Nuclear Ab, Type 1 | No | Yes |
| APBIS | AP3B2 IFA, S | No | Yes |
| CS2CS | CASPR2-IgG CBA, S | No | Yes |
| CRMS | CRMP-5-IgG, S | No | Yes |
| DPPCS | DPPX Ab CBA, S | Yes | Yes |
| LG1CS | LGI1-IgG CBA, S | No | Yes |
| PCAB2 | Purkinje Cell Cytoplasmic Ab Type 2 | No | Yes |
Reflex Tests
| Test ID | Reporting Name | Available Separately | Always Performed |
|---|---|---|---|
| AN1BS | ANNA-1 Immunoblot, S | No | No |
| AN2BS | ANNA-2 Immunoblot, S | No | No |
| CRMWS | CRMP-5-IgG Western Blot, S | Yes | No |
| DPPTS | DPPX Ab IFA Titer, S | No | No |
| AN1TS | ANNA-1 Titer, S | No | No |
| APBCS | AP3B2 CBA, S | No | No |
| APBTS | AP3B2 IFA Titer, S | No | No |
| CRMTS | CRMP-5-IgG Titer, S | No | No |
| PC2TS | PCA-2 Titer, S | No | No |
Testing Algorithm
If client requests or if the immunofluorescence assay (IFA) patterns suggest collapsin response-mediator protein-5 (CRMP-5)-IgG, then the CRMP-5-IgG IFA titer and CRMP-5-IgG Western blot will be performed at an additional charge.
If the IFA pattern suggests antineuronal nuclear antibody (ANNA)-1, then the ANNA-1 immunoblot, ANNA-1 titer, and ANNA-2 immunoblot will be performed at an additional charge.
If the IFA pattern suggests AP3B2 adaptor protein 3 beta2) antibodies, then the AP3B22 cell binding assay (CBA) and AP3B22 titer will be performed at an additional charge.
If the IFA pattern suggests PCA-2 antibody, then the PCA-2 IFA titer will be performed at an additional charge.
If dipeptidyl-peptidase-like protein-6 antibody (DPPX) antibody CBA result is positive, then the DPPX titer will be performed at an additional charge.
For more information see Autoimmune/Paraneoplastic Gastrointestinal Dysmotility Evaluation Algorithm.
Reporting Name
GI Dysmotility, Autoimm/Paraneo, SSpecimen Type
SerumSpecimen Minimum Volume
2 mL
Specimen Stability Information
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Serum | Refrigerated (preferred) | 28 days | |
| Frozen | 28 days | ||
| Ambient | 72 hours |
Reject Due To
| Gross hemolysis | Reject |
| Gross lipemia | Reject |
| Gross icterus | Reject |
Reference Values
|
Test ID |
Reporting Name |
Methodology* |
Reference Value |
|
AGIDI |
GI Dysmotility, Interpretation, S |
Medical interpretation |
Interpretive report |
|
GANG |
AChR Ganglionic Neuronal Ab, S |
RIA |
≤0.02 nmol/L |
|
ANN1S |
Anti-Neuronal Nuclear Ab, Type 1 |
IFA |
Negative |
|
APBIS |
AP3B2 IFA, S |
IFA |
Negative |
|
CS2CS |
CASPR2-IgG CBA, S |
CBA |
Negative |
|
CRMS |
CRMP-5-IgG, S |
IFA |
Negative |
|
DPPCS |
DPPX Ab CBA, S |
CBA |
Negative |
|
LG1CS |
LGI1-IgG CBA, S |
CBA |
Negative |
|
PCAB2 |
Purkinje Cell Cytoplasmic Ab Type 2 |
IFA |
Negative |
Reflex Information:
|
Test ID |
Reporting Name |
Methodology* |
Reference Value |
|
AN1BS |
ANNA-1 Immunoblot, S |
IB |
Negative |
|
AN1TS |
ANNA-1 Titer, S |
IFA |
<1:240 |
|
AN2BS |
ANNA-2 Immunoblot, S |
IB |
Negative |
|
APBCS |
AP3B2 CBA, S |
CBA |
Negative |
|
APBTS |
AP3B2 IFA Titer, S |
IFA |
<1:240 |
|
CRMTS |
CRMP-5-IgG Titer, S |
IFA |
<1:240 |
|
CRMWS |
CRMP-5-IgG Western Blot, S |
WB |
Negative |
|
DPPTS |
DPPX Ab IFA Titer, S |
IFA |
<1:240 |
|
PC2TS |
PCA-2 Titer, S |
IFA |
<1:240 |
*Methodology abbreviations used:
Immunofluorescence assay (IFA)
Cell-binding assay (CBA)
Western blot (WB)
Radioimmunoassay (RIA)
Immunoblot (IB)
Neuron-restricted patterns of IgG staining that do not fulfill criteria for ANNA-1, CRMP-5-IgG, or PCA-2 may be reported as "unclassified anti-neuronal IgG." Complex patterns that include nonneuronal elements may be reported as "uninterpretable."
CRMP-5 titers lower than 1:240 are detectable by recombinant CRMP-5 Western blot analysis. CRMP-5 Western blot analysis will be done on request on stored serum (held for 4 weeks). This supplemental testing is recommended in cases of chorea, vision loss, cranial neuropathy, and myelopathy. Call 1-800-533-1710 to request CRMP-5 Western blot.
Day(s) Performed
Report Available
8 to 12 daysSpecimen Retention Time
28 daysPerforming Laboratory
Mayo Clinic Laboratories in Rochester
CPT Code Information
83519
86255 x 7
84182 AN1BS (if appropriate)
86256 AN1TS (if appropriate)
84182 AN2BS (if appropriate)
86255 APBCS (if appropriate)
86256 APBTS (if appropriate)
86256 CRMTS (if appropriate)
84182 CRMWS (if appropriate)
86255 DPPCS (if appropriate)
86256 DPPTS (if appropriate)
86256 PC2TS (if appropriate)
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| GID2 | GI Dysmotility, Autoimm/Paraneo, S | 97557-3 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| 34269 | GI Dysmotility, Interpretation, S | 69048-7 |
| 80150 | ANNA-1, S | 33615-6 |
| 83077 | CRMP-5-IgG, S | 72504-4 |
| 84321 | AChR Ganglionic Neuronal Ab, S | 94694-7 |
| 83138 | PCA-2, S | 84925-7 |
| 64279 | LGI1-IgG CBA, S | 94287-0 |
| 64281 | CASPR2-IgG CBA, S | 94285-4 |
| 64933 | DPPX Ab CBA, S | 94676-4 |
| 615863 | AP3B2 IFA, S | 101907-4 |
| 618899 | IFA Notes | 48767-8 |
Special Instructions
Forms
If not ordering electronically, complete, print, and send Gastroenterology and Hepatology Test Request (T728) with the specimen